Ann: Half Year Results Analyst Presentation, page-8

this result is above expectations. a few points:
1) they just upgraded npat outlook from 1.48-1.55bill range up to 1.55-1.6bill range. taking the midpoints of 1.115 to 1.575 thats a 60million dollar upgrade.

2) sequiris is tracking above expectations

3) all segments are tracking as expected or better

4) capex is being invested heavily for pushing into china, transplant, stem cell and csl-112 into cardiovascular; all these are massive potential earnings drivers a few years from now. even if only 1-2 come off they will drive a further stepchange in eps.

5) they are well funded for both r&d and m&a.

6) they mention a new fc mumtimer molecule in phase 1 trials but not much detail... a little teaser for the imagination.

7) rising dividends by >20% to reward long term investors (although small yield relative to sp, this underpins the sp and rewards those who have held since buying in at much lower sp).

8) aud to usd should be lower over the next 12mo as interest rates rise in usa but not in aus and commodities resurgence in aus is not pushing aud higher at present. this is a further tailwind if aud drops to say 75c.

9) tax reform in usa benefits csl with a direct earnings boost that goes durectly to eps which kicks in now from 1/1/18.

all in all this announcement is a positive one so if the broader market sentiment remains positive we should rechallenge 150 and push higher to 155 over coming months.
my plan: im holding tight the shares i purchased in 2016 at 85-90 but will look to trim if csl hits 155-160 as i think at tht point i should take profits and hope to buy back cheaper later (classic rookie error since csl rarely dips for long...haha).